Parathyroid AdenomasNCT07218224
Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas
A study testing 18F-Fluorocholine (FCH) and Positron emission tomography (PET) in people with Parathyroid Adenomas, run by Thomas Hope.
Trial summary
This expanded access protocol is proposed to allow University of California San Francisco (UCSF) patients additional access to 18F-fluorocholine (FCH) Positron Emission Tomography (PET) imaging for localization of parathyroid adenomas. Read more about this study
- Who is it for?
- Ages 13 years and older
- Conditions the study is for
- Parathyroid Adenomas
- What is being tested?
- 18F-Fluorocholine (FCH) and Positron emission tomography (PET)
- Type of treatment
- Injection or infusion, Surgery or procedure
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 years and older
- All sexes
- Child, Adult, Older adult
Who may be able to join
- Age ≥ 13 years.
- Evidence of primary hyperparathyroidism.
- Ability to understand a written informed consent document, and the willingness to sign it.
Who cannot join
- 1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
Trial locations and contacts
No sites are listed yet.
About this study
This expanded access protocol is proposed to allow University of California San Francisco (UCSF) patients additional access to 18F-fluorocholine (FCH) Positron Emission Tomography (PET) imaging for localization of parathyroid adenomas.
Read the detailed description
No health outcome measures will be obtained under this protocol.
- Conditions
- Parathyroid Adenomas
- Being tested
- 18F-Fluorocholine (FCH), Positron emission tomography (PET)
- Medical subject headings
- Parathyroid Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
18F-Fluorocholine (FCH)Drug
Also called FCH, 18F-fluorocholine (fluoromethyl-(2-hydroxyethyl)-dimethylazanium)
A dose of 4-7 millicurie (mCi) +/- 10% of radiotracer 18F-Fluorocholine (FCH) manufactured at UCSF will be given intravenously.
Positron emission tomography (PET)Procedure or surgery
Also called PET Scan
A scan is a procedure that produces images of organs and tissues used in conjunction with a radiotracer.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parathyroid AdenomasStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Thomas Hope
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Thomas Hope, University of California, San Francisco
- Investigators
- Thomas Hope, MD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07218224
- Sponsor's protocol ID
- 25-44398
- Status last verified
- Oct 2025
- First submitted
- 2 Oct 2025
- Last updated
- 20 Oct 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas
- ClinicalTrials.gov ID
- NCT07218224
- Acronym / sponsor ID
- 25-44398
- Conditions
- Parathyroid Adenomas
- Study type
- Expanded access
- Recruitment status
- Available
- Lead sponsor
- Thomas HopeUniversity, hospital or other
- First posted
- 20 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This expanded access protocol is proposed to allow University of California San Francisco (UCSF) patients additional access to 18F-fluorocholine (FCH) Positron Emission Tomography (PET) imaging for localization of parathyroid adenomas.
Detailed description
No health outcome measures will be obtained under this protocol.
Study design
Who may qualify
- Ages
- 13 years and older
- Sex
- All
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Age ≥ 13 years.
- Evidence of primary hyperparathyroidism.
- Ability to understand a written informed consent document, and the willingness to sign it.
Key exclusion criteria (1 listed)
- 1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 18F-Fluorocholine (FCH)Also: FCH, 18F-fluorocholine (fluoromethyl-(2-hydroxyethyl)-dimethylazanium)A dose of 4-7 millicurie (mCi) +/- 10% of radiotracer 18F-Fluorocholine (FCH) manufactured at UCSF will be given intravenously. | Drug | – |
| Positron emission tomography (PET)Also: PET ScanA scan is a procedure that produces images of organs and tissues used in conjunction with a radiotracer. | Procedure or surgery | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2025.
Related trials for Parathyroid Adenomas
RecruitingEarly Phase 1
Flurpiridaz F-18 PET/CT Imaging for Detecting Parathyroid Adenomas
Hyperparathyroidism
RecruitingPhase 2/3
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
Primary Hyperparathyroidism, Parathyroid Cancer
Enrolling by invitationObservational study
Parathyroid Adenoma Detection With Rubidium-82 Imaging
Parathyroid Adenomas, Hyperparathyroidism, Primary
Active, not recruitingPhase 2
Agnostic Therapy in Rare Solid Tumors
Urachal Cancer, Parathyroid Carcinoma
RecruitingPhase 2/3
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
Parathyroid Adenoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas Hope, MD principal investigator
University of California, San Francisco
Questions about this trial
What is this clinical trial studying?
A study testing 18F-Fluorocholine (FCH) and Positron emission tomography (PET) in people with Parathyroid Adenomas, run by Thomas Hope.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Maya Aslam ((415)514-8987, maya.aslam@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2025.